EVM
FLNA

Eaton Vance Management’s Filana Therapeutics FLNA Stock Holding History

Eaton Vance Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-75
Closed -$3K – 2536
2021
Q4 		$3K Hold
75
– – ﹤0.01% 2710
2021
Q3 		$0 Sell
75
-100
-57% -$8.35K ﹤0.01% 2577
2021
Q2 		$15K Buy
+175
New +$9.37K ﹤0.01% 2484

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Eaton Vance Management's FLNA Position: Q1 2022 in Review

Eaton Vance Management sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 75 shares — an estimated $3K sold.

Eaton Vance Management first reported a position in FLNA in Q2 2021 and held it in 3 quarters. The position peaked at $15K in Q2 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

  • Eaton Vance Management reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 75 Filana Therapeutics shares in Q1 2022, an estimated $3K.
  • Eaton Vance Management first reported a position in Filana Therapeutics in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Filana Therapeutics position peaked at $15K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.